COMP <GO>
TCRT vs MTVA // EV/EBITDA & P/E VALUATION
Alaunos Therapeutics Inc. (NASDAQ) VS. MetaVia Inc. (NASDAQ) • 15-METRIC TALLY: TCRT 2
— MTVA 1
■ METRIC PARITY
LAST: $1.89 (-11.27%) • MKT CAP: $7.8M
valuation
—
LAST: $1.19 (+4.39%) • MKT CAP: $7.8M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TCRT VS. MTVA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TCRT | MTVA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -50.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | TCRT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.0 | 32.2 | +17.86 | TCRT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.8M | $7.8M | -$37.1K | MTVA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TCRT REV | MTVA REV | TCRT GROSS % | MTVA GROSS % | TCRT FCF | MTVA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.0K | $0 | — | — | -$3.0M | -$15.7M |
| FY 2024 | $10.0K | $0 | — | — | -$5.0M | -$24.7M |
| FY 2023 | $5.0K | $0 | — | — | -$30.1M | -$10.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TCRT // BETA —
MTVA // BETA —